Fig. 8: Pilot pharmacokinetic study to determine scIgG-306C7B3 and scIgG-anti-FITC exposure. | npj Parkinson's Disease

Fig. 8: Pilot pharmacokinetic study to determine scIgG-306C7B3 and scIgG-anti-FITC exposure.

From: AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies

Fig. 8

(Thy-1)-[A30P] hα-synuclein mice were unilaterally inoculated into the striatum at 2.0 × 1010 vector genomes with either AAV2HBKO-scIgG-anti-FITC or AAV2HBKO-scIgG-306C7B3. Plasma as well as CSF fluid was analyzed in transduced animals after 28, 42 and 56 days (separate cohorts for each individual time point). a Plasma and cerebrospinal fluid (CSF) exposure measuring 306C7B3 with a MSD based ELISA. b Plasma and CSF exposure of the control anti-FITC antibody. Analysis as in (a). Taking all data together, an approximate ratio of plasma to CSF exposure of 12.6:1 has been calculated for scIgG-306C7B3. Data presented as mean plus s.e.m. (n = 8 animals per group).

Back to article page